asulacrine has been researched along with Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afzal, A; Sarfraz, M; Sun, J; Wang, G; Wu, Z | 1 |
| Baguley, BC; Carmichael, J; Fyfe, D; Gardner, C; Houghton, J; Langley, RE; Osborne, L; Pagonis, C; Price, C; Woll, PJ | 1 |
| Benson, L; Doroshow, JH; Grove, WR; Maroun, JA; Mittelman, A; Robert, F; Rosen, PJ; Sklarin, NT; Stewart, JA; Wiernik, PH | 1 |
| Baguley, BC; Evans, P; Grillo-Lopez, AJ; Grove, W; Hardy, JR; Harvey, VJ; Paxton, JW; Smith, S | 1 |
1 review(s) available for asulacrine and Neoplasms
| Article | Year |
|---|---|
Integrated scientific data bases review on asulacrine and associated toxicity.
Topics: Amsacrine; Animals; Antineoplastic Agents; Humans; Neoplasms; Oxidative Stress; Signal Transduction | 2016 |
2 trial(s) available for asulacrine and Neoplasms
| Article | Year |
|---|---|
A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Area Under Curve; Bone Marrow Diseases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase II Inhibitors | 2001 |
A phase II trial of CI-921 in advanced malignancies.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1992 |
1 other study(ies) available for asulacrine and Neoplasms
| Article | Year |
|---|---|
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms | 1988 |